Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tackles bone pain caused by chemo-boosting drug

NCT ID NCT07192770

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood, and sleep. The goal was to learn better ways to manage this side effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

225 people

The number who actually took part.

Started

Sep 2025

Finished

Feb 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male and female patients (aged 18-70 years) with histologically or cytologically confirmed solid tumors, receiving chemotherapy and prophylactic G-CSF at Ankara Etlik City Hospital. Participants will be consecutively recruited, without randomization, as part of routine clinical care. The study population represents a real-world oncology cohort, designed to capture the prevalence, severity, and management of G-CSF-induced bone pain and related quality-of-life outcomes.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-70 years * Histologically or cytologically confirmed solid tumor * Receiving chemotherapy with prophylactic or secondary prophylactic G-CSF (filgrastim, pegfilgrastim, or lipegfilgrastim) * ECOG performance status 0-3 * Able to complete patient-reported outcome questionnaires (VAS, QLQ-C30, FACT-G, FACT-F, PHQ-9, GAD-7, BDI, PSQI) * Written informed consent provided Exclusion Criteria: * Known bone metastases (confounds bone pain assessment) * Use of NSAIDs, opioids, or antihistamines within 48 hours prior to G-CSF administration * Patients not indicated for G-CSF prophylaxis * Severe cognitive impairment or communication barrier preventing completion of questionnaires * Active concurrent malignancy requiring systemic therapy * Known hypersensitivity to G-CSF or supportive care medications * Investigator judgment that participation may compromise data integrity or patient safety * ECOG performance status 4

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced neutropenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity Depression Fatigue insomnia neoplasm neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced neutropenia Solid tumors

Contacts and locations

Locations

  • Etlik City Hospital Medical Oncology Department

    Ankara, Yenimahalle, 06270, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.